Skip to main content

Table 1 Demographic and clinical information

From: Association of Alzheimer’s and Lewy body disease pathology with basal forebrain volume and cognitive impairment

 

Pure AD

(N = 248)

Pure LBD

(N = 22)

Mixed AD/LBD

(N = 185)

Group differences

Age at death

82.0 (10.1)

80.1 (11.4)

79.7 (9.3)

BF10 = 0.62a

Last visit - death (years)

1.8 (1.8)

1.4 (1.3)

1.9 (2.2)

BF10 = 0.09a

Last MRI - death (years)

5.1 (3.1)

5.1 (3.0)

5.2 (3.0)

BF10 = 0.04a

Male: female, N (%)

131:117 (53%:47%)

19:3

(86%:14%)

117:68 (63%:37%)

BF10 = 5.8b

Years of education

15.5 (3.0)

15.7 (3.7)

15.4 (3.2)

BF10 = 0.05a

APOE ε4 allele, N (%)

143 (61%)

6 (30%)

108 (60%)

BF10 = 0.43c

Cognitive status, N (%)

  

BF10 = 0.25d

 

 normal cognition

7 (2.8%)

1 (5%)

2 (1%)

 
 

 impaired-not-MCI

2 (0.8%)

0

0

 
 

 MCI

22 (8.9%)

2 (9%)

6 (3%)

 
 

 dementia

217 (88%)

19 (86%)

177 (96%)

 

Primary etiological diagnosis based on clinical informatione

 
 

 AD

209 (87%)

7 (33%)

151 (83%)

 
 

 LBD

12 (5%)

13 (62%)

22 (12%)

 
 

 Vascular impairment

8 (3%)

0

3 (2%)

 
 

 FTLD

4 (2%)

0

3 (2%)

 
 

 other

6 (3%)

1 (5%)

2 (1%)

 

CDR global

1.84 (0.96)

1.59 (0.93)

1.95 (0.92)

BF10 = 0.19a

Geriatric depression scale

2.2 (2.3)

3.2 (2.0)

2.6 (2.7)

BF10 = 0.26a

Neuropath findings, N (%)

  
 

 Braak stage III/IV

41 (17%)

-

36 (19%)

 
 

 Braak stage V/VI

207 (83%)

-

149 (81%)

 
 

 Moderate NP

86 (35%)

-

58 (31%)

 
 

 Frequent NP

162 (65%)

-

127 (69%)

 
 

 Brainstem-predominant LB

-

6 (27%)

19 (10%)

 
 

 Limbic or amygdala-predominant LB

-

8 (36%)

93 (50%)

 
 

 Neocortical LB

-

8 (36%)

73 (40%)

 
 

 Presence of vascular pathology

244 (98%)

22 (100%)

183 (99%)

BF10 = 0.26f

 

 TDP-43 sum score

0.84 (1.36)

0.89 (1.27)

0.95 (1.26)

BF10 = 0.10g

  1. Mean (standard deviation), if not otherwise specified. All clinical information from last visit before death
  2. a Bayesian ANOVA
  3. b Bayesian contingency tables test (independent multinomial); post-hoc pairwise comparisons: pure AD vs. pure LBD: BF10 = 10.9, pure AD vs. mixed AD/LBD: BF10 = 1.3, pure LBD vs. mixed AD/LBD: BF10 = 1.2
  4. c Bayesian contingency tables test (independent multinomial); available for 235 pure AD, 20 pure LBD, and 179 mixed AD/LBD
  5. d Bayesian contingency tables test (independent multinomial)
  6. e only applicable to those without normal cognition; information missing for 2 pure AD, and 2 mixed AD/LBD
  7. f presence of ischemic, hemorrhagic or vascular pathology; Bayesian contingency tables test (independent multinomial); available for 247 pure AD, 22 pure LBD, 184 mixed AD/LBD
  8. g score from 0–4 calculated as the sum of regional TDP-43 scores in amygdala, hippocampus, entorhinal/inferior temporal cortex and neocortex; Bayesian ANOVA; available for 96 pure AD, 9 pure LBD, 77 mixed AD/LBD
  9. CDR, Clinical Dementia Rating; LB, Lewy bodies; MCI, mild cognitive impairment; NP, neuritic plaques